AngioDynamics (ANGO) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic transformation and portfolio evolution

• Transitioned from a legacy-focused company to a growth-oriented med tech innovator, emphasizing high-growth, high-margin cardiovascular and cancer markets.

• Pruned non-core assets through divestitures and a key acquisition, reallocating resources to R&D and regulatory expansion.

• Med Tech segment now represents 43% of revenue, up from 17%, and is projected to grow 12–15% YoY, driving gross margin accretion and future growth.

• Med Device segment provides stable cash flow and earnings, supporting investment in Med Tech innovation.

• International expansion is underway, with CE marks for AlphaVac and Auryon and a growing global sales force.

Product innovation and clinical advancements

• NanoKnife received FDA approval and CPT code for intermediate-risk prostate cancer, targeting a $7–900M U.S. market and $2.5B globally, with PRESERVE study showing 84% disease-free rate and minimal side effects.

• AlphaVac and AngioVac address the fast-growing PE and thrombectomy markets, with AlphaVac outperforming competitors and both systems offering unique aspiration and reinfusion capabilities.

• Auryon laser system for PAD has treated over 100,000 patients, surpassed $150M in cumulative sales since 2020, and is gaining share from established players.

• Ongoing clinical trials and regulatory milestones include AlphaVac PE FDA and CE Mark, Auryon PAD CE Mark, and NanoKnife CPT code and prostate tissue indication.

• Robust R&D pipeline and clinical investments are driving expansion into new indications and markets.

Financial performance and operational efficiency

• Achieved positive EBITDA for the first six months and guided for full-year profitability, with expectations for sustained EBITDA and cash flow positivity.

• Company maintains a debt-free, strong balance sheet and expects to be adjusted EBITDA positive by FY2025 and cash flow positive by FY2026.

• FY2025 guidance projects $282–$288 million in revenue, with flat Med Device sales.

• Manufacturing transition to Costa Rica aims to reduce $15M in overhead and improve gross and EBITDA margins by FY2027.

• Med Tech gross margins in the mid-60s, compared to mid-40s for Med Device, supporting long-term margin expansion.